Academic Journal
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
| العنوان: | Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. |
|---|---|
| المؤلفون: | Katz, Deborah A, Morris, Joan D, Chu, Michael P, David, Kevin A, Thieblemont, Catherine, Morley, Nicholas J, Khan, Sharif S, Viardot, Andreas, Martín García-Sancho, Alejandro, Rodríguez-García, Guillermo, Bastos-Oreiro, Mariana, Lee, Seung Tae, Kormany, William, Chen, Yuqi, Wong, Hansen L, Anderson, Abraham A, Katlinskaya, Yuliya, Avilion, Ariel A, Dai, Tian, González-Barca, Eva |
| سنة النشر: | 2022 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | Relapsed/refractory, blinatumomab, high-risk DLBCL, Adult, Antibodies, Bispecific, Humans, Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-2, Remission Induction |
| الوصف: | This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3-5 and/or double-/triple-hit or double MYC/BCL-2 expressors) who achieved complete response (CR), partial response (PR), or stable disease (SD) following run-in with 6 cycles of R-chemotherapy (NCT03023878). Of the 47 patients enrolled, 28 received blinatumomab. Five patients (17.9%) experienced grade 4 treatment-emergent adverse events of interest (neutropenia, n = 4; infection, n = 1). Two deaths reported at the end of the study were unrelated to treatment with blinatumomab (disease progression, n = 1; infection, n = 1). 3/4 patients with PR and 4/4 patients with SD after R-chemotherapy achieved CR following blinatumomab. Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1029-2403 |
| Relation: | http://hdl.handle.net/10668/19676; https://doi.org/10.1080/10428194.2022.2064981 |
| DOI: | 10.1080/10428194.2022.2064981 |
| الاتاحة: | http://hdl.handle.net/10668/19676 https://doi.org/10.1080/10428194.2022.2064981 |
| Rights: | Attribution-NonCommercial-NoDerivatives 4.0 International ; http://creativecommons.org/licenses/by-nc-nd/4.0/ ; open access |
| رقم الانضمام: | edsbas.13C8DEF8 |
| قاعدة البيانات: | BASE |
| تدمد: | 10292403 |
|---|---|
| DOI: | 10.1080/10428194.2022.2064981 |